Navigation Links
Current Blood Thinners Face Tough Competition

Studies provide more evidence that newcomers hold mettle against warfarin, aspirin

FRIDAY, Feb. 26 (HealthDay News) -- New studies provide more proof that the mainstays of anti-clotting therapy, namely warfarin and aspirin, are facing some severe competition from newcomers.

Researchers presenting their findings during a Friday news conference at the American Stroke Association's annual meeting in San Antonio show that one new drug, dabigatran (Pradaxa), which is not yet approved in the United States, equaled warfarin for treating stroke patients, while cilostazol (Pletal), which has been approved by the U.S. Food and Drug Administration for the treatment of peripheral arterial disease (PAD), outperformed aspirin in preventing recurrent strokes.

Other researchers presented evidence that high-intensity movement exercise assisted by a robot or a human can improve functioning and quality of life in stroke survivors years after the event. It has long been thought that improvements could only be garnered in the early days following a stroke.

The Pradaxa trial included 3,623 patients with atrial fibrillation and a previous stroke who were randomized to receive warfarin, a low dose of Pradaxa (110 milligrams) twice a day or a higher dose (150 mg) of Pradaxa twice a day for about two years.

The rate of stroke or transient ischemic attack (TIA) in those taking warfarin was 2.74 percent a year and 2.32 percent a year for those taking Pradaxa, not a significant difference.

The lower dose of Pradaxa also caused less bleeding and was easier to manage than warfarin, a famously difficult drug to administer and monitor.

"In contrast to warfarin, dabigatran is given in a fixed dose twice daily independent of body weight, sex, food, whatever, and you don't need to monitor the coagulation system," study author Dr. Hans-Christoph Diener, chairman of neurology at University Hospital in Essen, Germany, said during the news conference.

"In patients who already had a transient ischemic attack or stroke and suffer from atrial fibrillation, dabigatran is as effective as warfarin," he added. "And it's much easier to handle."

Patients receiving Pradaxa had more heart attacks than those taking warfarin, but the absolute difference was small, the authors stated. Also, Pradaxa patients had higher rates of gastrointestinal bleeding.

The study was funded by Boehringer-Ingelheim GmbH, which makes this drug.

A second trial pitted the clot-busting drug Pletal against aspirin and found that Pletal was superior in preventing recurrent strokes without the bleeding complications associated with aspirin.

Among 2,700 stroke patients in the trial, those taking Pletal were 25.7 percent less likely to have a stroke than those taking aspirin. The authors had expected the stroke rate to be the same between the two groups.

"We conclude that the cilostazol is one of the options for the secondary prevention of stroke in patients who can tolerate long-term administration of this drug," said study author Dr. Yukito Shinohara, head of neurology at Tachikawa Hospital in Tokyo.

This trial was funded by Otsuka Pharmaceutical Co., Ltd, which makes cilostazol.

The final study turned to technology to help patients severely debilitated by a stroke.

"Upper extremity impairment is very common after a stroke and there are very few therapeutic options for people with chronic stroke and few studies on rehabilitation," said study author Dr. Albert C. Lo, a neurologist at the VA Medical Center and an assistant professor of neurology at Brown University in Providence, R.I.

Patients receiving high-intensity movement therapy -- either from a human or a robot -- experienced improved functioning in their arm and improved quality of life compared with patients getting "usual care."

"High-intensity movement matters for these individuals," said Lo. "Getting them to move their arm on a regular basis and practice results in a fairly modest improvement. We're not talking about curing anyone. There are modest but consistent improvements in quality of life."

The robot-assisted protocol cost about the same as conventional therapy -- about $3 a day over a year, if you exclude the actual cost of the robot.

More information

The American Stroke Association has more on stroke.

SOURCES: Feb. 26, 2010, news conference with Yukito Shinohara, M.D., head, neurology, Tachikawa Hospital, Tokyo; Hans-Christoph Diener, M.D., Ph.D., professor and chairman, neurology, University Hospital, Essen, Germany; Albert C. Lo, M.D., neurologist, VA Medical Center, and assistant professor, neurology, Brown University, Providence, R.I.

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
2. Children can have recurrent strokes
3. Announces the Addition of Fully Accredited Law and Criminal Justice Degree Programs to its Current Website Offerings
4. Current Smoking Can Worsen Lung Cancer
5. Is Obesity a Disease? Current Research, Facts, Figures, and the Pros and Cons at New Website
6. American Scientific CE Removed - Now Current Information
7. CAHU and NAHU Weigh in on Current Form of H. R. 3590
8. Anthem Blue Cross and Blue Shield In Missouri Urges Missouri Senators Claire McCaskill and Christopher S. Bond to Not Support the Current Senate Health Care Reform Legislation
9. Connectyx Attains Current Listing Status on Pink Sheets Exchange
10. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis
11. National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: